Your browser doesn't support javascript.
loading
Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia / 中国当代儿科杂志
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-689592
Responsible library: WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To study the effects of minimal residual disease (MRD) level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia (B-ALL).</p><p><b>METHODS</b>A total of 152 children with newly-diagnosed B-ALL who had complete remission after the first cycle of the chemotherapy and had complete follow-up information were enrolled in this study. According to the MRD detection by flow cytometry on day 33 of remission induction, they were divided into three groups standard-risk (SR) group (MRD <10; n=60), intermediate-risk (IR) group (10≤ MRD <10; n=55), and high-risk (HR) group (MRD ≥10; n=37). Nested RT-PCR was used to determine the IKZF1 genotype of all children before chemotherapy. The effects of MRD level on day 33 of remission induction and IKZF1 genotype on the recurrence-free survival (RFS) of children with B-ALL were analyzed.</p><p><b>RESULTS</b>There were 7 common IKZF1 subtypes in all the 152 children with B-ALL IK1, IK2/3, IK4, IK6, IK8, IK9, and IK10. Of the 152 children, 130 had functional subtypes of IKZF1 and 22 had non-functional subtypes of IKZF1. During the follow-up period, relapse occurred in 26 (17%) children, and the recurrence rate was highest in the HR group (P<0.05). However, there was no significant difference in the recurrence rate between the SR group and the IR group (P>0.05). The cumulative recurrence rate of the children with non-functional subtypes of IKZF1 was significantly higher than that of those with functional types of IKZF1 (P<0.01). The predicted 5-year RFS rates in the SR, IR, and HR groups were (94.2±2.9)%, (86.7±3.8)%, and (56.2±4.5)% respectively (P<0.05). The 5-year RFS rate of the children with functional subtypes of IKZF1 was significantly higher than that of those with non-functional subtypes of IKZF1 (P<0.01). There was no significant difference in the predicted 5-year RFS rate between the children with functional subtypes of IKZF1 and those with non-functional subtypes of IKZF1 in the SR group (P>0.05). However, the predicted 5-year RFS rate of the children with functional subtypes of IKZF1 was significantly higher than that of those with non-functional subtypes of IKZF1 in the IR group and the HR group (P<0.05).</p><p><b>CONCLUSIONS</b>B-ALL children with non-functional subtypes of IKZF1 have a high recurrence rate, and the recurrence rate will be even higher in B-ALL children with non-functional subtypes of IKZF1 and MRD ≥10 on day 33 of chemotherapy.</p>
Subject(s)
Full text: Available Health context: SDG3 - Health and Well-Being / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases / SDG3 - Target 3.2 Reduce avoidable death in newborns and children under 5 Health problem: Target 3.2: Reduce avoidable death in newborns and children under 5 / Leukemia / Noncommunicable Diseases Database: WPRIM (Western Pacific) Main subject: Prognosis / Recurrence / Survival / Therapeutics / Remission Induction / Antineoplastic Combined Chemotherapy Protocols / Mortality / Neoplasm, Residual / Ikaros Transcription Factor / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Prognostic study Limits: Child / Child, preschool / Female / Humans / Male Language: Chinese Journal: Chinese Journal of Contemporary Pediatrics Year: 2018 Document type: Article
Full text: Available Health context: SDG3 - Health and Well-Being / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases / SDG3 - Target 3.2 Reduce avoidable death in newborns and children under 5 Health problem: Target 3.2: Reduce avoidable death in newborns and children under 5 / Leukemia / Noncommunicable Diseases Database: WPRIM (Western Pacific) Main subject: Prognosis / Recurrence / Survival / Therapeutics / Remission Induction / Antineoplastic Combined Chemotherapy Protocols / Mortality / Neoplasm, Residual / Ikaros Transcription Factor / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Prognostic study Limits: Child / Child, preschool / Female / Humans / Male Language: Chinese Journal: Chinese Journal of Contemporary Pediatrics Year: 2018 Document type: Article
...